--- title: "Cerebrolysin | PepTracker Pro" description: "A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Cerebrolysin", "description": "A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions.", "url": "https://peptrackerpro.com/peptides/cerebrolysin", "lastReviewed": "2026-06-22", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Cerebrolysin", "item": "https://peptrackerpro.com/peptides/cerebrolysin" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching neuroprotective therapies?", "acceptedAnswer": { "@type": "Answer", "text": "Cerebrolysin is a research peptide studied in preclinical models. A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions." } }, { "@type": "Question", "name": "Those exploring stroke recovery options?", "acceptedAnswer": { "@type": "Answer", "text": "Cerebrolysin is a research peptide studied in preclinical models. A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions." } }, { "@type": "Question", "name": "Healthcare providers studying neurodegenerative treatment adjuncts?", "acceptedAnswer": { "@type": "Answer", "text": "Cerebrolysin is a research peptide studied in preclinical models. A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Cerebrolysin **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # Cerebrolysin Medium Evidence A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions. Aliases FPF 1070 +1 more Evidence Medium Evidence Last Updated 2026-06-22 Reading Time 2 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Why Researchers Study It](#why-researchers-study) 3. [Proposed Mechanisms](#proposed-mechanisms) 4. [Evidence Snapshot](#evidence-snapshot) 5. [Commonly Discussed Benefits](#benefits) 6. [Safety & Cautions](#safety) 7. [Comparisons](#comparisons) 8. [Calculator Tools](#calculator) 9. [Citations](#citations) ## What It Is Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue via standardized enzymatic proteolysis. It has been approved in over 40 countries for stroke recovery, traumatic brain injury (TBI), and dementia — but remains unapproved by the FDA in the United States. Multiple randomized controlled trials have evaluated its neuroprotective potential: in vascular dementia, a 24-week RCT found ADAS-cog+ improvements of 10.6 points vs 4.4 for placebo. A meta-analysis of mild-to-moderate Alzheimer's disease trials concluded a favorable benefit-risk ratio, though Cochrane reviewers have called for larger, more rigorous studies. In post-TBI recovery, a 2025 review in a pharmacology journal synthesized preclinical and clinical evidence supporting Cerebrolysin's neurotrophic factor-like activity, including BDNF and GDNF modulation, synaptogenesis promotion, and anti-apoptotic effects. Adverse reactions are generally mild and transient (vertigo, agitation, feeling hot). As of 2026, no new pivotal trials have been announced, but Cerebrolysin continues to be used clinically in Europe, Asia, and Latin America as an adjunctive neuroprotective therapy. Also known as: FPF 1070, brain-derived peptide preparation ## Why Researchers Study It Cerebrolysin is one of the few clinically available neuropeptide preparations with decades of use across multiple countries. Its multi-target neurotrophic mechanism — affecting BDNF, synaptogenesis, and anti-apoptosis simultaneously — makes it a unique research subject for understanding peptide-based neuroprotection in stroke, TBI, and neurodegenerative disease. ## Proposed Mechanisms - Mimics neurotrophic factors (BDNF, GDNF, CNTF) to support neuronal survival - Promotes synaptogenesis and dendritic branching in damaged brain regions - Exhibits anti-apoptotic properties in ischemic and traumatic brain injury models - Modulates neuroinflammatory cascades following acute brain injury - Enhances cholinergic transmission relevant to cognitive function ## Evidence Snapshot Medium Evidence Low Medium High Study Type Model Outcome Link RCT (multicenter) Vascular dementia — 24 weeks ADAS-cog+ improvement of 10.6 points vs 4.4 placebo [Source](https://pubmed.ncbi.nlm.nih.gov/20656516/) Meta-analysis Mild-to-moderate Alzheimer's disease Overall beneficial effect with favorable benefit-risk ratio [Source](https://pubmed.ncbi.nlm.nih.gov/25832905/) Review (2025) Post-TBI recovery — preclinical and clinical evidence synthesis Neurotrophic factor-like activity supporting neuroprotection; BDNF/GDNF modulation documented [Source](https://www.sciencedirect.com/science/article/abs/pii/S2452014425000755) ## Commonly Discussed Benefits [Neuroprotection](/benefits/neuroprotection)[Cognition](/benefits/cognition)[Recovery](/benefits/recovery) Researching Cerebrolysin ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=cerebrolysin) ## Safety & Cautions - Not FDA-approved in the United States - Must be administered intravenously under medical supervision - Clinical trial results have been mixed - Cochrane reviews have called for more rigorous studies ## Comparisons See how Cerebrolysin compares to related peptides: [Cerebrolysin vs CAQK](/compare/cerebrolysin-vs-caqk) [Cerebrolysin vs Davunetide](/compare/cerebrolysin-vs-davunetide) [Cerebrolysin vs Dihexa](/compare/cerebrolysin-vs-dihexa) [Cerebrolysin vs P21](/compare/cerebrolysin-vs-p21) [Cerebrolysin vs Selank](/compare/cerebrolysin-vs-selank) [Cerebrolysin vs Semax](/compare/cerebrolysin-vs-semax) [Cerebrolysin vs Trofinetide](/compare/cerebrolysin-vs-trofinetide) [Cerebrolysin vs Trontinemab](/compare/cerebrolysin-vs-trontinemab) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Bornstein NM. et al. — Cerebrolysin in acute ischemic stroke. J Neurol Sci. 2018 [PubMed](https://pubmed.ncbi.nlm.nih.gov/) 2. \[2\] Guekht AB. et al. — Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. 2010 [PubMed](https://pubmed.ncbi.nlm.nih.gov/20656516/) 3. \[3\] Cerebrolysin in post-TBI recovery: Pharmacology and clinical evidence — ScienceDirect 2025 [PubMed](https://www.sciencedirect.com/science/article/abs/pii/S2452014425000755) 4. \[4\] Alvarez XA. et al. — Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. 2015 [PubMed](https://pubmed.ncbi.nlm.nih.gov/25832905/) ### Keep researching in the app - Log Cerebrolysin to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=cerebrolysin) [Browse more peptides](/peptides) ## Related Peptides ### CAQK Medium Evidence A brain-targeting tetrapeptide studied for neuroprotection and targeted drug delivery to injured brain and spinal cord tissue. [Neuroprotection](/benefits/neuroprotection)[brain-health](/benefits/brain-health)[targeted-delivery](/benefits/targeted-delivery)[Inflammation](/benefits/inflammation) [View Details](/peptides/caqk) [\+ Compare](/compare?select=caqk)[](https://app.peptrackerpro.com/?add=caqk) ### Davunetide Low Evidence An eight-amino-acid ADNP-derived peptide studied for microtubule stabilization, tau-related neuroprotection, and rare ADNP syndrome. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection) [View Details](/peptides/davunetide) [\+ Compare](/compare?select=davunetide)[](https://app.peptrackerpro.com/?add=davunetide) ### Dihexa Low Evidence A hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[Anti-Aging](/benefits/anti-aging) [View Details](/peptides/dihexa) [\+ Compare](/compare?select=dihexa)[](https://app.peptrackerpro.com/?add=dihexa) ### P21 Medium Evidence An 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[brain-health](/benefits/brain-health)[memory](/benefits/memory) [View Details](/peptides/p21) [\+ Compare](/compare?select=p21)[](https://app.peptrackerpro.com/?add=p21) ### Selank Medium Evidence A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties. [Anxiety Relief](/benefits/anxiety-relief)[Mood](/benefits/mood)[Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)+1 more [View Details](/peptides/selank) [\+ Compare](/compare?select=selank)[](https://app.peptrackerpro.com/?add=selank) ### Semax Medium Evidence A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[Mood](/benefits/mood)[Recovery](/benefits/recovery) [View Details](/peptides/semax) [\+ Compare](/compare?select=semax)[](https://app.peptrackerpro.com/?add=semax) ### Trofinetide High Evidence A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization. [Neuroprotection](/benefits/neuroprotection) [View Details](/peptides/trofinetide) [\+ Compare](/compare?select=trofinetide)[](https://app.peptrackerpro.com/?add=trofinetide) ### Trontinemab Medium Evidence An investigational, brain-penetrant anti-amyloid antibody from Roche/Genentech that uses the proprietary 'Brainshuttle' transferrin-receptor delivery system to reach the brain far more efficiently than conventional antibodies. Trontinemab (development codes RG6102 / RO7126209) is a 2+1 bispecific molecule: it fuses the amyloid-beta-clearing antibody gantenerumab to a fragment that grabs transferrin receptor 1 (TfR1) on blood-brain-barrier cells, hitching a ride into the brain via the same receptor-mediated transport that carries iron. That shuttle lets a low intravenous dose clear amyloid plaques rapidly and deeply while triggering strikingly little of the brain swelling and micro-bleeding (ARIA) that limits approved anti-amyloid drugs. In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), the 3.6 mg/kg dose removed roughly 107 centiloids of amyloid after 28 weeks, driving about 91-92% of participants below the amyloid-positivity threshold (24 centiloids) - with ARIA-E seen in fewer than 5% of participants, well below the ~13% reported for lecanemab and ~24% for donanemab. On the strength of those data, Roche launched two identical pivotal Phase 3 trials - TRONTIER 1 and TRONTIER 2 - in early symptomatic Alzheimer's disease (about 1,600 patients across 18 countries, begun in 2025), and at the 2026 Alzheimer's Association International Conference (AAIC) in London it unveiled PrevenTRON, a Phase 3 prevention trial in 1,600 cognitively unimpaired people at high risk (elevated plasma p-tau217). Trontinemab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. [cognitive-health](/benefits/cognitive-health)[Neuroprotection](/benefits/neuroprotection)[amyloid-clearance](/benefits/amyloid-clearance)[alzheimers (investigational)]() [View Details](/peptides/trontinemab) [\+ Compare](/compare?select=trontinemab)[](https://app.peptrackerpro.com/?add=trontinemab) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.